The Efficacy of Enteric-coated Mycophenolate Sodium (EC-MPS) (Myfortic) in The Treatment of Relapse or Resistant Proliferative Lupus Nephritis

Inclusion Criteria: * age 16 years of above at the time of screening * ability and willingness to provide written informed consent (or to obtain consent from parent guardian where applicable) and to comply with the schedule of protocol requirements * Diagnosis of SLE according to ACR criteria. At least 4 criteria must have been present for the diagnosis of SLE. The 4 criteria do not have to be present at the time of screening * Active lupus nephritis defined as follows: Biopsy proven (within 16 weeks prior to screening) ISN Class III or IV (A or A/C) not include III(C) IV(C) and VI (\>90% chronic irreversible scarring) * Relapse or resistant to (3 consecutive doses) IVCY * Resistant lupus or Relapse lupus nephritis defined as follows: * Increase in serum creatinine \>/= 0.3 mg/dl or * Increase in proteinuria \> 1.5 g/day (which must have improved by ≥ 50% in the preceding 3 months) * Life-time cumulative dose of IVCY \> 6 grams * Female patients of childbearing potential must have a negative serum pregnancy Exclusion Criteria: Relates to SLE * Diagnosis of rapid progressive glomerulonephritis (RPGN): doubling serum creatinine and/or crescentic glomeruli ≥ 30% * Severe renal impairment as defined by calculated creatinine clearance or MDRD-GFR \< 30 ml/min(except creatinine clearance or MDRD-GFR \> 50 ml/min in the 12 weeks prior to screening) * History of serious disease or complication in any organ system that not appropriate to treatment immunosuppressive drug groups. * Severe extra-renal organ involvement Related to Treatment * Previous of any Mycophenolate groups in the 6 months prior to screening * Treatment with any investigational drugs in the 3 months prior to screening Related to General Health * Pregnancy or breast feeding mothers. * Concomitant condition which has required treatment moderate to high dose steroid in the 12 weeks prior to screening. * Evidence of significant uncontrolled concomitant disease in any organ system not related to SLE. * History of cancer, including solid tumors, hematological malignancies and carcinoma. * Evidence of current abuse of drugs or alcohol. Related to Laboratory Findings * Neutrophile \< 1,500/mm3, Hb \< 7g/L, Platelet \< 50,000/mm3 (except active SLE) * Positive HBsAg or anti-HCV or anti-HIV.